DealZone

Deals wrap: Teva trumps rival to win Cephalon bid

May 2, 2011

The world’s largest generic drugmaker, Teva Pharmaceutical Industries plans to buy U.S. specialty drugmaker Cephalon for $6.8 billion,  topping an unsolicited bid by Canadian rival Valeant Pharmaceuticals International.

Warner Music’s $3 billion buyout could be done by the end of the week, according to a person familiar with the matter. Final buyout bids for the company are due today. Warner Music’s board effectively put itself up for sale in January when it appointed Goldman Sachs and AGM Partners to assess interest from external parties.

Danisco, the Danish food ingredients and enzymes producer urged shareholders to accept a higher takeover bid from chemicals group DuPont as fund managers welcomed the “decent offer” and said it would likely succeed. DuPont raised its offer for Danisco by 5 percent to 700 Danish crowns ($139) per share from 665, making its cash offer worth $6.64 billion.

Arch Coal said it will acquire International Coal Group in a $3.4 billion all-cash transaction to create the second-largest U.S. producer of steel-making coal. The news boosted International Coal shares in premarket trading.

Quest Diagnostics announced last month it would buy genetic-testing firm Celera Corp for $671 million, but word of a crucial scientific study helped the company negotiate a nearly $200 million discount in its deal. In this Wall Street Journal article, author John Jannarone asks, just how did Quest learn of the study months prior to its official publication?

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/